	US 11,903,927 B2
	Combination treatment of cancer
Nils Aage Brünner, Hellerup (DK); Palle Christophersen, Ballerup (DK); Jan Stenvang, Copenhagen K (DK); Jens Lichtenberg, Græsted (DK); and Annemette Thougaard, Kongens Lyngby (DK)
Assigned to Scandion Oncology A/S, Copenhagen N (DK)
Filed by Scandion Oncology A/S, Copenhagen N (DK)
Filed on Jul. 29, 2021, as Appl. No. 17/388,208.
Application 17/388,208 is a division of application No. 16/302,195, granted, now 11,103,481, previously published as PCT/EP2017/061823, filed on May 17, 2017.
Claims priority of application No. PA201670325 (DK), filed on May 17, 2016.
Prior Publication US 2021/0353596 A1, Nov. 18, 2021
Int. Cl. A61K 31/41 (2006.01); A61P 35/00 (2006.01); A61K 33/243 (2019.01); A61K 31/138 (2006.01); A61K 31/337 (2006.01); A61K 31/495 (2006.01); A61K 31/513 (2006.01); A61K 31/566 (2006.01); A61K 31/4745 (2006.01); C07D 257/04 (2006.01)

CPC A61K 31/41 (2013.01) [A61K 31/138 (2013.01); A61K 31/337 (2013.01); A61K 31/4745 (2013.01); A61K 31/495 (2013.01); A61K 31/513 (2013.01); A61K 31/566 (2013.01); A61K 33/243 (2019.01); A61P 35/00 (2018.01); C07D 257/04 (2013.01)]

19 Claims

1. A method of sensitizing cancer cells of a cancer to an anti-cancer agent or potentiating the therapeutic effect of an anti-cancer agent comprising administering to a subject in need thereof an effective amount of a VRAC modulator and an effective amount of an anti-cancer agent; wherein the cancer is selected from the group consisting of: colorectal cancer, breast cancer, lung cancer (non small cell lung cancer and small cell lung cancer), glioblastomas, head and neck cancers, malignant melanomas, basal cell skin cancer, squamous cell skin cancer, liver cancer, pancreatic cancer, prostate cancer, anal cancer, cervix uteri cancer, bladder cancer, corpus uteri cancer, ovarian cancer, gall bladder cancer, sarcomas, leukemias (myeloid and lymphatic), lymphomas, and myelomatosis.